deferoxamine has been researched along with Memory Disorders in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because the neurotoxic mechanisms of MSUD are poorly understood, this study aimed to evaluate the effects of chronic administration of a BCAA pool (leucine, isoleucine and valine)." | 1.39 | Chronic administration of branched-chain amino acids impairs spatial memory and increases brain-derived neurotrophic factor in a rat model. ( Bogo, MR; Comim, CM; Ferreira, GC; Gelain, DP; Moreira, JC; Oliveira, GM; Pasquali, MA; Quevedo, J; Scaini, G; Schuck, PF; Streck, EL, 2013) |
| " Here, we investigated whether acute and chronic administration of a BCAA pool causes impairment of acquisition and retention of avoidance memory in young rats." | 1.38 | Antioxidant administration prevents memory impairment in an animal model of maple syrup urine disease. ( Comim, CM; Dominguini, D; Ferreira, GC; Jeremias, IC; Mina, F; Morais, MO; Pescador, B; Quevedo, J; Scaini, G; Schuck, PF; Streck, EL; Teodorak, BP, 2012) |
| "In the first case, paranoid delusions, visual hallucinations, seizures and deteriorating speech followed each dialysis treatment with DFO." | 1.28 | Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. ( McCauley, J; Sorkin, MI, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fine, JM | 2 |
| Renner, DB | 2 |
| Forsberg, AC | 1 |
| Cameron, RA | 1 |
| Galick, BT | 1 |
| Le, C | 1 |
| Conway, PM | 1 |
| Stroebel, BM | 1 |
| Frey, WH | 2 |
| Hanson, LR | 2 |
| Zhang, XY | 1 |
| Cao, JB | 1 |
| Zhang, LM | 1 |
| Li, YF | 1 |
| Mi, WD | 1 |
| Scaini, G | 2 |
| Teodorak, BP | 1 |
| Jeremias, IC | 1 |
| Morais, MO | 1 |
| Mina, F | 1 |
| Dominguini, D | 1 |
| Pescador, B | 1 |
| Comim, CM | 2 |
| Schuck, PF | 2 |
| Ferreira, GC | 2 |
| Quevedo, J | 3 |
| Streck, EL | 2 |
| Baillargeon, AM | 1 |
| Hoerster, NS | 1 |
| Tokarev, J | 1 |
| Colton, S | 1 |
| Pelleg, A | 1 |
| Andrews, A | 1 |
| Sparley, KA | 1 |
| Krogh, KM | 1 |
| Guo, C | 1 |
| Wang, T | 1 |
| Zheng, W | 1 |
| Shan, ZY | 1 |
| Teng, WP | 1 |
| Wang, ZY | 1 |
| Oliveira, GM | 1 |
| Pasquali, MA | 1 |
| Gelain, DP | 1 |
| Moreira, JC | 1 |
| Bogo, MR | 1 |
| de Lima, MN | 2 |
| Dias, CP | 1 |
| Torres, JP | 1 |
| Dornelles, A | 1 |
| Garcia, VA | 1 |
| Scalco, FS | 2 |
| Guimarães, MR | 2 |
| Petry, RC | 1 |
| Bromberg, E | 2 |
| Constantino, L | 2 |
| Budni, P | 1 |
| Dal-Pizzol, F | 2 |
| Schröder, N | 2 |
| Presti-Torres, J | 1 |
| Caldana, F | 1 |
| Grazziotin, MM | 1 |
| Franke, SI | 1 |
| Henriques, JA | 1 |
| Barichello, T | 1 |
| Machado, RA | 1 |
| Valvassori, SS | 1 |
| Réus, GZ | 1 |
| Martins, MR | 1 |
| Petronilho, F | 1 |
| Ritter, C | 1 |
| McCauley, J | 1 |
| Sorkin, MI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An N of One Clinical Trial to Pilot the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment[NCT02878538] | Early Phase 1 | 0 participants (Actual) | Interventional | 2018-01-31 | Withdrawn (stopped due to Study was withdrawn before IRB approval) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for deferoxamine and Memory Disorders
| Article | Year |
|---|---|
Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; bet | 2015 |
Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice.
Topics: Animals; Caspase 3; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Encephal | 2015 |
Antioxidant administration prevents memory impairment in an animal model of maple syrup urine disease.
Topics: Acetylcysteine; Amino Acids, Branched-Chain; Animals; Antioxidants; Deferoxamine; Disease Models, An | 2012 |
Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Deferoxamine; Glycogen Synthase Kinas | 2012 |
Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, An | 2013 |
Chronic administration of branched-chain amino acids impairs spatial memory and increases brain-derived neurotrophic factor in a rat model.
Topics: Acetylcysteine; Amino Acids, Branched-Chain; Animals; Antioxidants; Brain-Derived Neurotrophic Facto | 2013 |
Reversion of age-related recognition memory impairment by iron chelation in rats.
Topics: Aging; Animals; Brain; Deferoxamine; Iron; Memory Disorders; Rats; Rats, Wistar; Recognition, Psycho | 2008 |
Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats.
Topics: Animals; Animals, Newborn; Deferoxamine; Iron; Male; Memory Disorders; Neuroprotective Agents; Rats; | 2007 |
Antioxidant treatment prevented late memory impairment in an animal model of sepsis.
Topics: Acetylcysteine; Animals; Antioxidants; Avoidance Learning; Cecum; Deferoxamine; Disease Models, Anim | 2007 |
Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
Topics: Aged; Aluminum Hydroxide; Deferoxamine; Hallucinations; Humans; Male; Memory Disorders; Middle Aged; | 1989 |